195 related articles for article (PubMed ID: 28780726)
1. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
Kim JH; Kim BJ; Jang HJ; Kim HS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis.
Kim HD; Kim BJ; Kim HS; Kim JH
Korean J Intern Med; 2019 May; 34(3):608-617. PubMed ID: 29334722
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
Min SJ; Jang HJ; Kim JH
Oncotarget; 2016 May; 7(19):27848-54. PubMed ID: 27036043
[TBL] [Abstract][Full Text] [Related]
4. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
5. Comparing RECIST with EORTC criteria in metastatic bladder cancer.
Öztürk H
J Cancer Res Clin Oncol; 2016 Jan; 142(1):187-94. PubMed ID: 26208817
[TBL] [Abstract][Full Text] [Related]
6. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors.
Aras M; Erdil TY; Dane F; Gungor S; Ones T; Dede F; Inanir S; Turoglu HT
Nucl Med Commun; 2016 Jan; 37(1):9-15. PubMed ID: 26440568
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review.
Kim JH
Oncotarget; 2016 Sep; 7(36):58105-58110. PubMed ID: 27517621
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.
Kim JH
Oncotarget; 2016 Mar; 7(12):13680-7. PubMed ID: 26885610
[TBL] [Abstract][Full Text] [Related]
9. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
[TBL] [Abstract][Full Text] [Related]
10. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
11. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
12. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.
Pinker K; Riedl C; Weber WA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):55-66. PubMed ID: 28361188
[TBL] [Abstract][Full Text] [Related]
13. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging.
Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P; Buvat I
J Nucl Med; 2011 Mar; 52(3):354-61. PubMed ID: 21345787
[TBL] [Abstract][Full Text] [Related]
14. PET response criteria in solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue sarcoma.
Fendler WP; Lehmann M; Todica A; Herrmann K; Knösel T; Angele MK; Dürr HR; Rauch J; Bartenstein P; Cyran CC; Hacker M; Lindner LH
J Nucl Med; 2015 Apr; 56(4):530-7. PubMed ID: 25722445
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
[TBL] [Abstract][Full Text] [Related]
16. RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
Litière S; Isaac G; De Vries EGE; Bogaerts J; Chen A; Dancey J; Ford R; Gwyther S; Hoekstra O; Huang E; Lin N; Liu Y; Mandrekar S; Schwartz LH; Shankar L; Therasse P; Seymour L;
J Clin Oncol; 2019 May; 37(13):1102-1110. PubMed ID: 30860949
[TBL] [Abstract][Full Text] [Related]
17. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
Liu K; Li G; Fan C; Zhou C; Li J
Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
[TBL] [Abstract][Full Text] [Related]
19. Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Kanazu M; Maruyama K; Ando M; Asami K; Ishii M; Uehira K; Minomo S; Matsuda Y; Kawaguchi T; Atagi S; Ogawa Y; Kusunoki Y; Takada M; Kubo A
Clin Lung Cancer; 2014 May; 15(3):182-7. PubMed ID: 24518101
[TBL] [Abstract][Full Text] [Related]
20. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer.
Kim HS; Kim JH; Yang I
Lung Cancer; 2014 Sep; 85(3):385-9. PubMed ID: 25074845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
